Low-dose naltrexone shows promise for long COVID

New Zealand Doctor Rata Aotearoa

David Codyre

Wednesday 8 January 2025

Psychiatrist David Codyre reviews the growing evidence for low-dose naltrexone in the treatment of functional syndromes such as fibromyalgia, chronic fatigue and long COVID

Key points, In low doses (typically 3–4.5mg daily), naltrexone appears to modulate  ... 

Subscription required: Follow link i f you have, or want, a subscription to this medical website

Beyond Antivirals: Alternative Therapies for Long COVID

Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou

19 November 2024

Viruses

Medexpress.pl > Medexpress blogosphere (en)
Dr. Marek Derkacz, MBA

POTS in Long-COVID: The hidden culprit of chronic fatigue and dizziness

MedExpress Team
Dr n. med. Marek Derkacz

Published Dec. 27, 2024 

With No Approved Treatments and Little Support, People With Long COVID Turn to Online Drug Markets
People are trying off-label medications, including some approved for treatment of HIV, hepatitis C or acute COVID-19.

December 17, 2024 • By Hannah Buttle and The Sick Times

Key points you should know:

American Family Physician Community Blog

Lilian White, MD
Posted on November 4, 2024

https://www.aafp.org/pubs/afp/afp-community-blog/entry/management-of-pots-due-to-long-covid.html

 Linda Elsegood interviewing Andrea, a patient from the United States who has been taking low dose naltrexone (LDN) to manage her health concerns.

Experts Develop Multimodal Approach for Treating Long COVID, Other Post-Acute Infectious Syndromes
Pharmacy Times, September 13, 2024
By Luke Halpern, Assistant Editor

An international team of researchers has proposed a multimodal approach involving a mixture of physical and pharmacological interventions to treat post-acute infectious syndromes (PAIS), including the condition known as long COVID that affects survivors of SARS-CoV-2 infection, the virus that causes COVID-19.

News Medical Life Sciences
Genomic Press
Sep 4 2024

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

BY Kenny Cheng August 19, 2024

Yale Medicine